RNA Analytical/Quality Videos

31. Approving The World's First saRNA Vaccine: Arcturus' Regulatory Experience 5/10/2024

    Explore the behind-the-scenes best practices of the company implemented that led to the approval of the world’s first saRNA vaccine in Japan.

32. In Which Specific Areas Do mRNA Makers Need More Regulatory Guidance? 5/10/2024

    Experts from this Advancing RNA Live panel discuss the results from a poll question revealing the top three areas RNA industry experts would be most interested in seeing additional mRNA-specific guidance from regulatory agencies.

33. The Conjugation Conundrum: The Realities Of Conjugated LNP Manufacturing 2/24/2026

    In this Advancing RNA Live clip, CMC Consultant Sujit Jain explains the numerous ways that adding targeting ligands “stress tests” the standard LNP manufacturing platform, as well as outlines which capabilities are most important for companies to consider when selecting an outsourcing partner for their active delivery strategies.

34. A Wishlist For The Future: The Next Frontier Of The mRNA & Oligo Supply Chains 12/3/2025

    Here, Advancing RNA Live speakers Khaled Yamout, Sanofi’s Francoise Ribes, and Camp4’s Satya Kuchimanchi share which supply chain advancements they would like to see in the near future, as well as how they anticipate these changes & evolutions could impact each modality’s growth.

35. How A Sponsored CMC Platform Accelerates mRNA Projects Into The Clinic 1/31/2023

    Developing a client-sponsored Target Product Profile (TPP) and Analytical Target Profile (ATP) is critical to move your drug product to clinic efficiently and meet acceptance criteria.

36. Crafting A "Durable" Partnership: A Two-Pronged Approach

    Featured speakers for the "Got Raw Materials? The State Of The mRNA Supply Chain" event share how they are working to deepen their partnerships today.

37. mRNA/saRNA Manufacturing: Accelerate The Path To Clinic 3/22/2021

    Discover key upstream and downstream considerations for process development for RNA drug substance manufacturing and the parameters that need construct-specific optimization to increase yield and reduce impurities.

38. A Double-Edged Sword? Defining "Efficiency" In mRNA Process Development 8/22/2024

    In this clip from a recent Advancing RNA LIVE event, panelists address a question about where the best opportunities exist upstream and/or downstream to increase mRNA manufacturing efficiencies.

39. The Purification Dilemma: Balancing Upstream & Downstream Investment 10/15/2025

    This Advancing RNA Live clip dives into the biggest challenges in mRNA purification and the critical debate on where to focus investment. Here, our three mRNA PD experts argue for a holistic process development strategy, challenging the traditional wisdom of optimizing the upstream process at any cost.

40. Goldilocks & The Guidances: Finding "Just Right" For RNA Regulations 6/24/2025

    Do we need more specific regulatory guidance for every RNA modality and therapeutic approach? We asked and the Advancing RNA Live audience answered… Here, panelists Tiffany Lucas and Ulrike Jägle address the audience’s responses, as well as share their thoughts on just how prescriptive the future of regulatory guidance for RNA therapeutics approaches could/should be..